Abstract
As is the case with other pharmaceuticals, formulation development is one of the critical steps in developing a protein as a therapeutic product. Development of stable protein formulations may require even more resources and effort than conventional small molecule pharmaceuticals. Proteins typically have more stability issues as a result of their complexity and delicate structural stability. Fortunately, a great deal of research regarding protein stability has been conducted and this information is readily available in the literature (reviewed by Manning et al., 1989; Chen, 1992; Ahern and Manning, 1992a; Ahern and Manning, 1992b; Arakawa et al., 1993; Cleland et al., 1993; Wang and Pearlman, 1993; Pearlman and Wang, 1996; Volkin and Middaugh, 1997). Ultimately, it would be ideal to be able to develop a pure pharmaceutical containing only the native protein. However, it is not practical to have only the native form of a protein in the formulation because the protein must be purified from a complex biological mixture containing a pool of other proteins which includes misfolded, denatured, and degraded forms of the same protein. Furthermore, a major challenge is to maintain the integrity of the purified protein during routine pharmaceutical processing, storage, handling, and delivery to the patient. One could envision achieving this goal by developing a formulation with perfect stability, i.e., no physical and chemical change in the protein. Becauise proteins are complex molecules composed of numerous reactive chemical groups and delicate three-dimensional structures, identifying a set of conditions to keep all components stable is virtually impossible. In general, commercial therapeutic protein formulations are developed under the assumption that some degree of physicochemical changes will occur during storage and handling.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ahern, T.J. and Manning, M.C., 1992a. Stability of protein pharmaceuticals, Part A: Chemical and physical pathways of protein degradation. Pharm. Biotech. Ser. Volume 2. Plenum Press, N.Y.
Ahern, T.J. and Manning, M.C., 1992b. Stability of protein pharmaceuticals, Part B: In vivo pathways of degradation and strategies for protein stabilization. Pharm. Biotech. Ser. Volume 3. Plenum Press, N.Y.
Arakawa, T., Prestrelski, S., Kinney, W., and Carpenter, J.F., 1993. Factors affecting short-term and long-term stabilities of proteins. Adv. Drug Delivery Rev. 10:1.
Brewster, M.E., Hora, M.S., Simpkins, J.W., and Bodor, N., 1991. Use of 2-hydroxypropyl-beta-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs. Pharm. Res. 8:792.
Cleland, J.L., Powell, M.F., and Shire, S.J., 1993. The development of stable protein formulations—A close look at protein aggregation, deamidation and oxidation. Crit. Rev. Ther. Drug 11:60.
Chen, T., 1992. Formulation concerns of protein drugs. Drug Dev. Ind. Pharmacy, 18:1311.
Defelippis, M.R., Bakaysa, D.L., Bell, M.A., Heady, M.A., Li, S., Pye, S., Youngman, K.M., Radzuik, J., and Frank, B.H., 1998. Preparation and characterization of a cocrystalline suspension of [Lys(B28),Pro(B29)] human insulin analogue. J. Pharm. Sci. 87:170.
Fagain, C.O., 1995. Understanding and increasing protein stability. Biochimica et Biophysica Acta. 1252:1.
Francis, G.E., Fisher, D., Delgado, C., Malik, F., Gardiner, A., and Neale, D., 1998. PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques Int. J. Hematology. 68:1.
Fransson, J., Hallen, D., and Florin-Robertsson, E., 1997. Solvent effects on the solubility and physical stability of human Insulin-like Growth Factor I. Pharm. Res. 14:606.
Grimm, W., 1998. Extension of the international conference on harmonization tripatic guieline for stability testing of new drug substances and products to countries of climatic zones III and IV. Drug Dev. Indust. Pharm. 24:313.
Guerra, P.I., Acklin, C., Kosky, A.A., Davis, J.M., Treuheit, M.J., and Brems, D.N., 1998. PEGylation prevents the N-terminal degradation of megakaryocyte growth and development factor Pharm. Res. 15:1822.
Herron, J.N., Jiskoot, W., and Crommelin, D.J.A., 1995. Physical methods to characterize pharmaceutical proteins. Pharm. Biotech. Ser. Volume 7. Plenum Press, N.Y.
Jones, A.J.S., 1993. Analysis of polypeptides and proteins Adv. Drug Del Rev. 10:29.
Knepp, V.M., Muchnik, A., Oldmark, S., and Kalashnikova, L., 1998. Stability of nonaqueous suspension formulations of plasma derived factor IX and recombinant human alpha interferon at elevated temperatures. Pharm. Res. 15:1090.
Kolvenbach, C.G., Narhi, L.O., Philo, J.S., Li, T., Zhang, M., and Arakawa, T., 1997. Gran-ulocyte-colony stimulating factor maintains a thermally stable, compact, partially folded structure at pH 2 J. Pept. Res. 50:310.
Kommanaboyina, B. and Rhodes, C.T., 1999. Trends in stability testing with emphasis on stability during distribution and storage. Drug Dev. Indust. Pharm. 25:857.
Lam, X.M., Patapoff, T.W., and Nguyen, T.H., 1997. The effect of benzyl alcohol on recombinant human interferon-gamma Pharm. Res. 14:725.
Maa, Y.F. and Hsu, C.C., 1996. Aggregation of recombinant human growth hormone induced by phenolic compounds Int. J. Pharm. 140:155.
Manning, M.C., Matsuura, J.E., Kendrick, B.S., Meyer, J.D., Dormish, J.J., Vrkljan, M., Ruth, J.R., Carpenter, J.F., and Shefter, E., 1995. Approaches for increasing the solution stability of proteins Biotech. Bioeng. 48:506.
Manning, M.C., Patel, K., and Borchardt, R.T., 1989. Stability of protein pharmaceuticals. Pharm. Res. 6:903.
Matthews, B.R., 1999. Regulatory aspects of stability testing in Europe. Drug Dev. Indust. Pharm. 25:831.
Murby, M., Samuelsson, E., Nguyen, T.N., Mignard, L., Power, U., Binz, H., Uhlen, M., and Stahl, S., 1995. Hydrophobility engineering to increase solubility and stability of a recombinant protein from respiratory syncytial virus. Eur. J. Biochem. 230:38.
Nema, S., Washkuhn, R.J., and Brendel, RJ., 1997. Excipients and their use in injectable products PDA J. Pharm. Sci. Technol. 51:166.
Note for Guidance on Inclusion of Antioxidants and Antimicrobial Preservatives in Medicinal Products, 1997. (CPMP/CVMP/QWP/115/95) EMEA (7/97).
Pearlman, R. and Wang, Y.J., 1996. Formulation, characterization, and stability of protein drugs: case histories. Pharm. Biotech. Ser. Volume 9. Plenum Press, N.Y.
Powell, M.F., Nguyen, T., and Baloian, L., 1998. Compendium of excipients for parenteral formulations. PDA J. Pharm. Sci. Technol. 52:238.
Reubsaet, J.L.E., Beijnen, J.H., Bult, A., Van-Maanen, R.J., Marchai, J.A.D., and Under-berg, W.J.M., 1998. Analytical techniques used to study the degradation of proteins and peptides: chemical instability J. Pharm. Biomed. Anal. 17:955.
Roig, M.G. and Kennedy, J.F., 1995. Perspectives for biophysicochemical modifications of enzymes. J. Biomaterials Sci. Polymer Ed. 7:1.
Thompson, J.E., 1998. Practical Guide to Contemporary Pharmacy Practice. Lippincott Williams & Wilkins, Hagerstown, MD.
Volkin, D.B., Mach, H., and Middaugh, CR., 1997. Degradative covalent reactions important to protein Stability. Molec. Biotech. 8:5.
Wang, Y.J. and Hanson, M.A., 1988. Parenteral formulations of proteins and peptides: stability and stabilizers. J. Parent. Sci. Technol. 42:SS4.
Wang, Y.J. and Pearlman, R., 1993. Stability and characterization of protein and peptide drugs: case histories. Pharm. Biotech. Ser. Volume 5. Plenum Press, N.Y.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Chang, B.S., Hershenson, S. (2002). Practical Approaches to Protein Formulation Development. In: Carpenter, J.F., Manning, M.C. (eds) Rational Design of Stable Protein Formulations. Pharmaceutical Biotechnology, vol 13. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0557-0_1
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0557-0_1
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5131-3
Online ISBN: 978-1-4615-0557-0
eBook Packages: Springer Book Archive